-
Specific Gut Microbiome Changes in Myelodysplastic Neoplasms Linked to Inflammation2024 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Gut microbiota and health
Ekaterina Balaian, Katja Sockel, Manja Wobus, Maria Uhlig, Matthias Wolfgang Groß, Sebastian Zeißig, +3 more
2citations -
Postpartum Hemorrhage in Women with Von Willebrand Disease after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
Anne de Vaan, Jeroen C.J. Eikenboom, Marieke J.H.A. Kruip, Marieke C. Punt, Michiel Coppens, Laurens Nieuwenhuizen, +10 more
2citations -
High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort
Joost S.P. Vermaat, Pim G. N. J. Mutsaers, Sébastien Anguille, Maria Theresa Kuipers, Évelyne Willems, Tim J. A. Dekker, +14 more
2citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
1citations -
Consensus-Based Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice with a Focus on Patients with Cytopenias: Systematic Literature Review and Clinical Practice Recommendations from a Global Consensus Group
Claire N. Harrison, Prithviraj Bose, Martin H. Ellis, Vikas K Gupta, Jean‐Jacques Kiladjian, John O Mascarenhas, +3 more
1citations -
Health-Related Quality of Life of CML Patients Under 2nd or 3rd Line Bosutinib Is Not Impaired Significantly By Gastrointestinal Toxicity (GI Tox) but Influenced By Sex - Results from a Subanalysis of the Bosutinib Dose Optimization (BODO) Study (CML-VII) Trial of the German CML Study Group
Susanne Isfort, Dominik Georg Friedrich Wolf, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +11 more
1citations -
ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
Andreas Hochhaus, Susanne Saußele, François‐Xavier Mahon, Virginia Pilipovic, Yifan Zhang, Peter Schuld, +1 more
1citations -
Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study
Steffen Koschmieder, Eyck von der Heyde, Lambert Busque, Françoise Boyer‐Perrard, Timothy Devos, Francesco Passamonti, +9 more
1citations -
Post Hoc Analysis of the Effect of Pegcetacoplan Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels Greater Than 10 Grams per Deciliter2021 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, Nicole Straetmans, +5 more
1citations -
ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry
Katharina Kohlbrenner, Norbert Galuschek, Alice Charlotte Fabarius, Marcel Reiser, Klaus Fenchel, Eva Eßeling, +23 more
1citations